At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 8, 2026 at 08:30 ET
Vor Biopharma announced that China's NMPA conditionally approved telitacicept for IgA nephropathy, the first BAFF/APRIL-targeting therapy approved for IgAN globally. This is a major regulatory milestone that validates the drug's mechanism and supports Vor Bio's global development plans, though Vor Bio only holds ex-Greater China rights and the approval is in China, not the US/EU.
- NMPA conditionally approved telitacicept for adult IgAN patients
- First and only approved BAFF/APRIL-targeting therapy for IgAN
- Approval supported by Phase 3 TELIGAN trial: 59% UPCR reduction from baseline at Week 39, 55% placebo-adjusted reduction
- eGFR remained stable on telitacicept vs decline in placebo arm
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access